Cabotegravir sodium

MONDAY, July 29, 2024 -- In a research letter published online July 24 in the New England Journal of Medicine , the authors describe long-acting early viral inhibition (LEVI) among patients with acute HIV infection in the context of long-acting injectable cabotegravir (CAB-LA) preexposure prophylaxis (PrEP). The research was published to coincide with the 25th International AIDS Conference, held from July 22 to 26 in Munich. Noting that in the HIV Prevention Trials Network (HPTN) 083 and 084 trials, altered presentation of acute HIV infection in the context of CAB-LA PrEP, LEVI was observed, Raphael J. Landovitz, M.D., from the University of California in Los Angeles, and colleagues examined presentations of HIV infection involving LEVI and classic HIV infection. The authors note that cases involving LEVI were characterized by low or undetectable HIV viral load and reduced or delayed antibody production, and were usually clinically silent. HIV antigens, antibodies, RNA, and DNA levels were often near the level of detection of available assays, which may revert from reactive, indeterminate, or positive to nonreactive or negative, challenging confirmation of HIV. Forty-one HIV infections were identified among 3,446 participants who had been randomized to receive CAB-LA in trials HPTN 083 and 084; detection of an infection was delayed in 17 (41 percent) when an HIV rapid test and a HIV antigen and antibody test were used for screening. "When interpreting HIV test results in persons who are receiving CAB-LA PrEP, providers should recognize that a prolonged period of observation with frequent retesting may be needed before infection can be confirmed or ruled out," the authors write. Several authors disclosed ties to biopharmaceutical companies, including ViiV Healthcare and Gilead Sciences, which donated trial medications and matching placebos. ViiV Healthcare provided additional funding.

CHICAGO, July 28, 2024 /PRNewswire/ -- At ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo) in Chicago, more than 300 experts will present cutting-edge research and technology that will shape the future of laboratory medicine and improve patient care. From July 28-August 1, the meeting's 250-plus sessions will delve into a variety of timely topics, including the health consequences of ending federal protection for abortion in the U.S., a recent Food and Drug Administration (FDA) ruling that could significantly impede patient access to essential laboratory developed tests, and how to harness data science to achieve health equity. The case for clinical trials of lab tests. Clinical trials are the recognized standard for evaluating pharmaceuticals and other clinical interventions. In the meeting's opening plenary, Dr. Patrick M. Bossuyt will make a compelling, research-based argument for why clinical trials of laboratory tests should also be used to support practice guidelines, reimbursement decisions, and more. Dr. Bossuyt is the recipient of the 2024 Wallace H. Coulter Lectureship Award and a professor of clinical epidemiology at the University of Amsterdam. Lymphoma biomarkers and therapeutic targets from mass spectrometry-driven proteomics. Dr. Kojo S.J. Elenitoba-Johnson, chair of the department of pathology and laboratory medicine at Memorial Sloan Kettering Cancer Center, will deliver a plenary about the emergence of mass spectrometry as a way to assess complex protein mixtures in patient tissue samples, a technique that allows clinicians to detect cancer and develop more targeted treatments. Pharmacogenetic testing in precision health. In this plenary, Dr. Ron H.N. van Schaik, professor of pharmacogenetics at Erasmus University Medical Center, will explain how pharmacogenetics uses people's unique genetic profiles to develop personalized therapies for diseases. He'll describe recent challenges and successes in this field that could benefit patients in psychiatry, cardiology, and oncology, along with pharmacogenetic-testing developments that will further refine treatments. Providing more options in HIV prevention. Current HIV-prevention medications have limitations. Oral antiretrovirals combining tenofovir and emtricitabine reduce HIV only in certain people, while an injectable form of cabotegravir is effective but expensive. In this plenary, Dr. Sharon L. Hillier, director of reproductive infectious disease research at Magee-Womens Research Institute, will discuss the development of new prevention options for at-risk populations. Projected consequences of ending abortion protection. In this plenary, Dr. Diana Greene Foster, professor of obstetrics, gynecology, and reproductive sciences at the University of California, San Francisco, will discuss the changing landscape of abortion law and its impact on patient care. Drawing on data from nearly 1,000 pregnant people at 30 U.S. abortion facilities, she'll describe the health and socioeconomic consequences of receiving abortions versus carrying pregnancies to term. Special session on laboratory developed tests. This year, the FDA released a final rule placing laboratory developed tests under FDA oversight, even though these tests are already regulated by the Centers for Medicare & Medicaid Services. In this July 30 session, representatives from ADLM, the American Medical Association, and the Children's Hospital Association will discuss the negative impact this rule will have on patient care. They will be joined by a caregiver and patient advocate who will give the patient perspective on why laboratory developed tests are so important to timely diagnoses and treatment. The winning entry of the FairLabs Data Analytics Challenge. The University of Washington Department of Laboratory Medicine & Pathology Team has been named winner of a competition challenging participants to develop analytic tools that promote fairness in peripartum urine drug screening. ADLM 2024 attendees can learn about the winning entry and how to apply data science to health equity at the Health Equity & Access Division breakfast meeting on July 29. "From plenaries highlighting testing breakthroughs to a session on achieving health equity through data science, to a critical discussion of the FDA's laboratory developed tests ruling, ADLM 2024 showcases how clinical laboratory professionals are making bold moves every day to advance medicine around the globe," said ADLM CEO Mark J. Golden. Session information ADLM 2024 registration is free for members of the media. Reporters can register online here: Plenary sessions Session 11001 Why we need more strong clinical trials of laboratory tests Sunday, July 28 5-6:30 p.m. U.S. Central Time Session 12001 Lymphoma biomarkers and therapeutic targets from mass spectrometry-driven proteomics Monday, July 29 8:45-10 a.m. U.S. Central Time Session 13001 Implementation of PGx-based testing in precision health: Do you have your DNA-passport? Tuesday, July 30 8:45-10 a.m. U.S. Central Time Session 14001 Empowering choice by providing more options in HIV prevention Wednesday, July 31 8:45-10 a.m. U.S. Central Time Session 15001 Projected health and social consequences of ending the federal protection for abortion in the United States Thursday, August 1 8:45-10 a.m. U.S. Central Time All plenary sessions will take place in Room S100 of the McCormick Place Convention Center in Chicago. Special session on laboratory developed tests Session 13002 How FDA oversight of LDTs will affect patient care Tuesday, July 30 4:30-6 p.m. U.S. Central Time Room S100, McCormick Place Convention Center Presentation of the FairLabs Data Analytics Challenge winning entry Health Equity and Access Division and the Data Analytics in Laboratory Medicine Committee breakfast meeting Monday, July 29 7:30-9 a.m. U.S. Central Time Great Lakes Ballroom A, Marriott Marquis Chicago About ADLM 2024 ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo) offers 5 days packed with opportunities to learn about exciting science from July 28-August 1 in Chicago. Plenary sessions will explore the projected consequences of ending abortion protection, new HIV prevention options, lymphoma biomarkers and therapeutic targets, pharmacogenetic testing in precision health, and the need for clinical trials of laboratory tests. At the ADLM 2024 Clinical Lab Expo, more than 900 exhibitors will fill the show floor of the McCormick Place Convention Center in Chicago, with displays of the latest diagnostic technology, including but not limited to artificial intelligence, point-of-care, and automation. About the Association for Diagnostics & Laboratory Medicine (ADLM) Dedicated to achieving better health through laboratory medicine, ADLM (formerly AACC) brings together more than 70,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, ADLM has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit . Christine DeLong ADLM Associate Director, Communications & PR (p) 202.835.8722 [email protected] Molly Polen ADLM Senior Director, Communications & PR (p) 202.420.7612 (c) 703.598.0472 [email protected] SOURCE Association for Diagnostics & Laboratory Medicine (ADLM)